● Recruiting
Phase II
Respiratory / COPD / Asthma
Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older
A Phase 2b trial testing a single-dose vaccine against RSV and metapneumovirus in 8,000 adults aged 60+, measuring effectiveness, safety, and immune response.
16 Sep 2026
NCT07810010